New hope for rare brain diseases: long-term safety trial of nizubaglustat begins

NCT ID NCT07399704

First seen Feb 16, 2026 · Last updated May 15, 2026 · Updated 10 times

Summary

This study tests the long-term safety and effects of a daily drug called nizubaglustat in people with two rare genetic diseases that affect the brain: GM2 gangliosidosis and Niemann-Pick type C. About 21 participants who were in an earlier study or who are currently on another drug (miglustat) will take nizubaglustat. Researchers will monitor side effects, seizures, and disease markers over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GM2 GANGLIOSIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Associação Hospitalar de Prot à Infância Dr. Raul Carneiro

    RECRUITING

    Água Verde, Curitiba, 80250-060, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospital de Clinicas de Porto Alegre

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira

    RECRUITING

    Rio de Janeiro, 22250, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.